CABA

Cabaletta Bio, Inc.

12.15 USD
-0.73 (-5.67%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Cabaletta Bio, Inc. stock is down -8.78% since 30 days ago. The next earnings date is Aug 8, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 60% of the previous 4 May’s closed higher than April. In the last 8 Unusual Options Trades, there were 2 PUTs, 6 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
01 Apr 13:43 17 May, 2024 12.50 PUT 637 3063
04 Apr 18:13 17 May, 2024 17.50 CALL 206 711
25 Apr 14:02 16 Aug, 2024 12.50 CALL 250 0
25 Apr 14:03 19 Jul, 2024 12.50 CALL 250 7
25 Apr 14:07 19 Jul, 2024 12.50 CALL 250 7
25 Apr 14:12 19 Jul, 2024 12.50 CALL 250 7
25 Apr 14:46 16 Aug, 2024 12.50 CALL 250 0
17 May 17:42 17 May, 2024 12.50 PUT 3082 3175

About Cabaletta Bio, Inc.

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies.